Zymeworks Inc. (T:ZYME)

Business Focus: N/A

Get the company report for the most recent outlook updated daily

Sep 28, 2019 08:30 am ET

Zymeworks Announces Updated Single Agent Data for HER2-Targeted Bispecific Antibody ZW25 at European Society for Medical Oncology (ESMO) Congress

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced updated data from the ongoing multi-center Phase 1 clinical trial evaluating ZW25 in patients with HER2‑expressing solid tumors, including biliary tract cancer (BTC), colorectal cancer (CRC), gynecological cancers, and gastroesophageal adenocarcinoma (GEA), in a poster discussion presentation at the ESMO 2019 Congress, taking place September 27 - October 1 in Barcelona, Spain.

Sep 17, 2019 06:45 am ET

Zymeworks Announces New Chair of Board of Directors and Voluntary Delisting from the TSX

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, announced that Lota Zoth has been appointed as its Chair of the Board of Directors. Ms. Zoth succeeds Nick Bedford, who has retired from his functions as Chair and Board member. Mr. Bedford served as Board Chair since September 2004.

Aug 28, 2019 05:00 pm ET

Zymeworks to Participate in Upcoming Investor Conferences

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that management will participate in three upcoming investor conferences.

Aug 02, 2019 05:00 pm ET

Zymeworks Reports 2019 Second Quarter Financial Results

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported financial results for the second quarter ended June 30, 2019.

Jul 16, 2019 08:30 am ET

Celgene Selects Lead Oncology Therapeutic Candidate Under Bispecific Antibody Collaboration with Zymeworks

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that its global biopharma partner Celgene Corporation has selected a lead therapeutic candidate in oncology for further development and exercised its option to a commercial license under the companies’ 2014 Azymetric™ collaboration and licensing agreement. Zymeworks’ proprietary Azymetric technology platform enables the rapid development of bispecific and multifunctional therapeutics with broad potential for the treatment of cancer, inflammation, and i

Jun 24, 2019 10:04 am ET

Zymeworks Announces Closing of Public Offering and Exercise in Full of the Underwriters’ Over-Allotment Option to Purchase Additional Shares

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical stage biopharmaceutical company developing multifunctional biotherapeutics (the “Company”), announced today the closing of its previously announced underwritten public offering (the “Offering”). The Offering consisted of 7,013,892 common shares, including the exercise in full of the underwriters’ over-allotment option to purchase 1,458,336 additional shares, and, in lieu of common shares, to a certain investor, pre-funded warrants to purchase up to 4,166,690 common shares. The common shares were offered at a price to the public of US$18

Jun 19, 2019 09:19 pm ET

Zymeworks Announces Pricing of $175.0 Million Public Offering

Zymeworks Inc. (NYSE/TSX:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics (the “Company”), announced today the pricing of its previously-announced underwritten public offering (the “Offering”) of 5,555,556 common shares and, to a certain investor, pre-funded warrants to purchase up to 4,166,690 common shares. The common shares are being offered at a price to the public of US$18.00 per common share and the pre-funded warrants are being offered at a price of US$17.9999 per pre-funded warrant, for aggregate gross proceeds to the Company of

Jun 18, 2019 04:05 pm ET

Zymeworks Files Preliminary Prospectus Supplements for Offering of Common Shares and Pre-Funded Warrants

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, has today filed a preliminary prospectus supplement (the “Canadian Supplement”) to its Canadian short form base shelf prospectus dated March 6, 2019 (the “Base Prospectus”) in connection with an offering of its common shares and pre-funded warrants to purchase its common shares (the “Offering”). The Canadian Supplement was filed with the securities regulatory authorities in each of the provinces and territo

Jun 12, 2019 05:00 pm ET

Zymeworks to Present at Raymond James Life Sciences and MedTech Conference

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will present at the upcoming Raymond James Life Sciences and MedTech Conference taking place June 18-19, 2019 in New York, NY.

Jun 04, 2019 06:45 am ET

Zymeworks Adds Accomplished Biopharmaceutical Executives to its Board of Directors

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the appointment of two new independent members to its Board of Directors, further enhancing the Board’s commercial expertise. The new board members are Sue Mahony, Ph.D., MBA, a pharmaceutical executive with over 30 years of combined experience with Eli Lilly and Company (Lilly), Schering-Plough, Amgen, and Bristol-Myers Squibb, and Troy Cox, MBA, who has served in numerous senior leadership positions at leading

May 29, 2019 05:00 pm ET

Zymeworks' Lead Asset, ZW25, Granted Fast Track Designation from the FDA

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ZW25, a novel Azymetric™ bispecific antibody, for the first-line treatment of patients with HER2-overexpressing gastroesophageal adenocarcinoma in combination with standard of care chemotherapy.

May 29, 2019 06:45 am ET

Zymeworks Earns Milestone Payment in Merck Collaboration

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that it has earned a milestone payment from Merck (known as MSD outside the US and Canada) achieved under the companies’ 2014 research and license agreement. Zymeworks will receive US$2.0 million in connection with Merck’s completion of a late-stage preclinical study for a bispecific antibody candidate using Zymeworks’ proprietary Azymetric™ and EFECT™ therapeutic platforms.

May 28, 2019 06:45 am ET

Zymeworks to Present at Jefferies 2019 Global Healthcare Conference

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will present at the upcoming Jefferies 2019 Global Healthcare Conference taking place June 4-7, 2019 in New York, NY.

May 23, 2019 05:00 pm ET

Zymeworks Announces Corporate Update Conference Call

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that it will host a webcast and conference call to discuss progress on its 2019 corporate priorities, including clinical development plans for its lead therapeutic candidates as well as recently announced and established corporate partnerships.

May 16, 2019 06:45 am ET

Zymeworks and GSK Expand 2016 Azymetric™ Bispecific Agreement

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that GSK has expanded its 2016 licensing and collaboration agreement with Zymeworks for the research, development, and commercialization of bispecific antibodies across multiple disease areas. Under the expanded agreement, GSK will now have access to Zymeworks’ unique heavy-light chain pairing technology, part of its proprietary Azymetric™ platform. Zymeworks’ Azymetric platform enables the development of bispec

May 14, 2019 06:45 am ET

Zymeworks Enters its First ZymeLink™ Antibody-Drug Conjugate Platform Licensing Agreement with Iconic Therapeutics

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that it has entered into a licensing agreement that grants Iconic Therapeutics, Inc. (Iconic) non-exclusive rights to Zymeworks’ proprietary ZymeLink™ antibody-drug conjugate (ADC) platform for the development of its ICON-2 Tissue Factor ADC for cancer. This is the first collaboration leveraging the ZymeLink platform and represents Zymeworks’ third technology platform licensed to a collaborator.

May 03, 2019 06:45 am ET

Zymeworks Announces Election of Directors and Voting Results from Shareholder Meeting

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, is pleased to announce the detailed voting results on the items of business considered at its Annual General Meeting of Shareholders held on May 2, 2019 (the “Meeting”).

May 02, 2019 05:00 pm ET

Zymeworks Reports 2019 First Quarter Financial Results

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported financial results for the first quarter ended March 31, 2019.

Apr 30, 2019 06:45 am ET

Zymeworks Adds Experienced Executives to Management Team to Support Expanding Clinical Development

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced it has expanded its leadership team with the hiring of three new vice presidents to support the Company’s expanded global clinical development: Mark Hollywood, Senior Vice President, Technical and Manufacturing Operations; Neil Josephson, M.D., Vice President, Clinical Research; and Bruce Hart, Ph.D., Vice President, Regulatory Affairs. Zymeworks has also promoted David Poon, Ph.D., to Vice President, Bus

Apr 25, 2019 06:45 am ET

Daiichi Sankyo Selects Lead Candidate Built on Zymeworks’ Azymetric™ Bispecific Platform

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, and Daiichi Sankyo Company, Limited (“Daiichi Sankyo”) announced today that Daiichi Sankyo has exercised its option for a commercial license to a proprietary immuno-oncology bispecific built on Zymeworks’ Azymetric™ and EFECT™ platforms. Zymeworks will receive a US$3.5 million payment based on Daiichi Sankyo’s selection of the first of up to three lead product candidates under its collaboration agreements with Zymeworks.

Apr 23, 2019 06:45 am ET

Zymeworks to Present at Bloom Burton & Co. Healthcare Investor Conference 2019

Zymeworks Inc. (NYSE/TSX:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will present at the upcoming Bloom Burton & Co. Healthcare Investor Conference taking place April 30-May 1, 2019 in Toronto, Canada.

Apr 15, 2019 06:45 am ET

Zymeworks Opens Phase 2 Clinical Trial for ZW25 in First-Line HER2-Expressing Metastatic Gastroesophageal Cancers

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced it has initiated its global multicenter Phase 2 clinical trial evaluating ZW25 in combination with standard of care chemotherapy for the first-line treatment of HER2-positive metastatic gastric, gastroesophageal junction, and esophageal adenocarcinomas.

Mar 27, 2019 08:00 am ET

Positive Results and New Technology Give Rise to Antibody Dominance

Investorideas.com, a leading investor news resource covering biotech and pharma stocks releases a snapshot looking at the biopharmaceutical market and how monoclonal antibody research is gaining market dominance. GELifesciences.com, talking about...

Mar 06, 2019 05:00 pm ET

Zymeworks Reports 2018 Year-End Financial Results

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported financial results for the year ended December 31, 2018.

Mar 05, 2019 05:00 pm ET

Zymeworks to Present at Barclays 2019 Global Healthcare Conference

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will present at the upcoming Barclays Global Healthcare Conference taking place March 12-14, 2019 in Miami Beach, Florida.

Jan 17, 2019 05:00 pm ET

Zymeworks Reports Second Investigational New Drug (IND)-Submission Milestone Achieved in Lilly Collaboration

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported the achievement of a new development milestone in its collaboration with Eli Lilly and Company (“Lilly”). In accordance with Zymeworks’ 2014 licensing and collaboration agreement with Lilly, Zymeworks will receive a milestone payment of US$8.0 million for Lilly’s submission of an IND application for an immuno-oncology bispecific antibody enabled by Zymeworks’ proprietary Azymetric™ platform.

Jan 06, 2019 06:45 am ET

Zymeworks Highlights 2018 Achievements and Announces 2019 Priorities

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reviewed its key 2018 accomplishments and outlined the Company’s priorities for 2019.

Dec 08, 2018 08:00 am ET

Zymeworks Submits Investigational New Drug (IND) Application for ZW49 and Presents IND-Enabling Studies at the San Antonio Breast Cancer Symposium

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, presented IND-enabling data for ZW49, a novel biparatopic HER2-targeted ADC, at the San Antonio Breast Cancer Symposium in San Antonio, TX.

Nov 27, 2018 06:30 am ET

Zymeworks and BeiGene Announce License and Collaboration Agreement for Zymeworks’ HER2-Targeted Therapeutic Candidates, ZW25 and ZW49, in Asia-Pacific and Research and License Agreement for Zymeworks’

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, and BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that the two companies have entered into a strategic collaboration for the clinical development and commercialization of Zymeworks’ investigational ZW25 and ZW49 HER2-targeted bispecific ant

Nov 14, 2018 06:30 am ET

Zymeworks Announces Updated Clinical Data for Novel Bispecific Antibody, ZW25, Presented at the EORTC-NCI-AACR Symposium

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, announced today the plenary presentation of updated ZW25 clinical data by Murali Beeram, MD, a clinical investigator at the START Center for Cancer Care, San Antonio, Texas. Data from Zymeworks’ ongoing multi-center Phase 1 study showed single agent ZW25, a bispecific antibody, induced anti-tumor activity and was well tolerated in heavily pretreated patients with a variety of HER2-expressing cancers.

Nov 07, 2018 04:30 pm ET

Zymeworks to Present at Upcoming Investor Conferences

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will present at the upcoming Stifel 2018 Healthcare Conference taking place November 13-14, 2018 in New York, NY and at the Jefferies 2018 London Healthcare Conference taking place November 14-15, 2018 in London, England.

Nov 06, 2018 04:30 pm ET

Zymeworks Reports Financial Results for the Third Quarter of 2018

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported financial results for the third quarter ended September 30, 2018.

Oct 30, 2018 06:45 am ET

Zymeworks Announces Selection of ZW25 Abstract for Plenary Session Presentation at the 30th EORTC-NCI-AACR Symposium

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, announced today that its abstract describing new data from the Company’s adaptive Phase 1 clinical trial for ZW25 has been selected for a plenary session presentation at the 30th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics being held in Dublin, Ireland from November 13-16, 2018.

Oct 23, 2018 06:45 am ET

Zymeworks and LEO Pharma Enter into Bispecific Antibody Licensing and Research Collaboration

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, and LEO Pharma A/S, a global leader in medical dermatology, have entered into a licensing and research collaboration to discover and develop bispecific antibodies targeting cytokine-receptor pathways using Zymeworks’ antibody discovery capabilities and its proprietary Azymetric™ and EFECT™ platforms. LEO Pharma will have exclusive rights to further develop and commercialize two bispecific candidates in dermatology indications, whi

Oct 04, 2018 06:45 am ET

Zymeworks to Webcast R&D Briefing

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that it will webcast its R&D Briefing from 9:00 a.m. to 12:00 p.m. Eastern Time on Thursday, October 11, 2018 in New York City.

Sep 25, 2018 04:30 pm ET

Zymeworks to Present at Ladenburg Thalmann 2018 Healthcare Conference

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will present at the upcoming Ladenburg Thalmann 2018 Healthcare Conference taking place October 1-2, 2018 in New York, NY.

Sep 19, 2018 06:45 am ET

Zymeworks Names Anthony Polverino, Ph.D., Executive Vice President of Early Development and Chief Scientific Officer

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced it has named Anthony (Tony) Polverino, Ph.D., Executive Vice President of Early Development and Chief Scientific Officer. In his new role, Dr. Polverino will be instrumental in setting and driving Zymeworks’ R&D strategy. He will also manage the advancement of product candidates from discovery research through translational research/early development, thereby creating a seamless link with clinical development. In t

Sep 04, 2018 05:00 pm ET

Zymeworks Reports IND-Submission Milestone Achieved in Lilly Collaboration

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported the achievement of a development milestone in its collaboration with Eli Lilly and Company. In accordance with Zymeworks’ 2013 licensing and collaboration agreement with Lilly, Zymeworks will receive a milestone payment of US$2.0 million for Lilly’s submission of an IND application for a bispecific antibody enabled by Zymeworks’ proprietary Azymetric™ platform. Previously, Zymeworks announced Lilly’s nomination of t

Aug 29, 2018 04:30 pm ET

Zymeworks to Present at Wells Fargo Healthcare Conference

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will present at the upcoming 13th Annual Wells Fargo Securities Healthcare Conference taking place September 5-6, 2018 in Boston, MA.

Aug 02, 2018 08:00 am ET

Zymeworks to Present at Canaccord Genuity 38th Annual Growth Conference

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will present at the upcoming Canaccord Genuity 38th Annual Growth Conference taking place August 8-9, 2018 in Boston, MA, USA.

Aug 01, 2018 08:00 am ET

Zymeworks Reports Financial Results for the Second Quarter of 2018

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported financial results for the second quarter ended June 30, 2018.

Jun 11, 2018 09:36 am ET

Zymeworks Closes Previously Announced Public Offering

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, announced today that it has closed its previously announced underwritten public offering (the “Offering”) of 6,210,000 common shares, including the underwriters’ full exercise of their over-allotment option to purchase 810,000 additional shares, at a price to the public of US$15.75 per common share, for aggregate gross proceeds to the Com

Jun 07, 2018 07:50 pm ET

Zymeworks Announces Election of Directors and Voting Results from Shareholder Meeting

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, is pleased to announce the detailed voting results on the items of business considered at its Annual General and Special Meeting of Shareholders held on June 7, 2018 (the “Meeting”).

Jun 07, 2018 08:08 am ET

IIROC Trade Resumption - SMU.UN; PL; ZYME; APH; NVU.UN

TORONTO, June 7, 2018 /CNW/ - Trading resumes in:

Jun 06, 2018 10:49 pm ET

Zymeworks Announces Pricing of Public Offering

Zymeworks Inc. (NYSE/TSX:ZYME), a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, announced today the pricing of its previously- announced underwritten public offering (the “Offering”) of 5,400,000 common shares at a price to the public of US$15.75 per common share, for aggregate gross proceeds to the Company of approximately US$85.1 million, before deducting the underwriting discounts and commissions and estimated Offering ex

Jun 06, 2018 04:15 pm ET

IIROC Trading Halt - ZYME

TORONTO, June 6, 2018 /CNW/ - The following issues have been halted by IIROC:

Jun 06, 2018 04:10 pm ET

Zymeworks Files Preliminary Prospectus Supplement for Offering of Common Shares

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, has today filed a preliminary prospectus supplement (the “Supplement”) to its short form base shelf prospectus dated May 24, 2018 (the “Base Prospectus”) in connection with an offering of its common shares (the “Offering”). The Supplement was filed with the securities regulatory authorities in each of the provinces and territories of Cana

Jun 01, 2018 04:14 pm ET

IIROC Trade Resumption - ZYME

TORONTO, June 1, 2018 /CNW/ - Trading resumes in:

Jun 01, 2018 03:58 pm ET

IIROC Trading Halt - ZYME

TORONTO, June 1, 2018 /CNW/ - The following issues have been halted by IIROC:

Jun 01, 2018 03:45 pm ET

Clinical Data for Zymeworks’ Novel Bispecific Antibody, ZW25, Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, announced today the presentation of ZW25 clinical data by Funda Meric-Bernstam, MD, Principal Investigator for the ZW25 study at the University of Texas MD Anderson Cancer Center. Data from the ongoing multi-center Phase 1 study showed single agent ZW25 induced anti-tumor activity and was well tolerated in heavily pretreated patients across a range of HER2-expressing cancers.

May 14, 2018 05:00 pm ET

Zymeworks and Daiichi Sankyo Expand Immuno-Oncology Collaboration Focused on Bispecific Antibodies

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, and Daiichi Sankyo Company, Limited (Daiichi Sankyo) announced today that they entered into a new license agreement, building upon their 2016 cross-licensing and collaboration agreement.

May 10, 2018 04:30 pm ET

Zymeworks to Present at the UBS Global Healthcare Conference 2018

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will present at the upcoming UBS Global Healthcare Conference taking place May 21-23, 2018 in New York, NY, USA.

May 01, 2018 04:05 pm ET

Zymeworks Reports 2018 First Quarter Financial Results

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported financial results for the quarter ended March 31, 2018.

Apr 30, 2018 04:05 pm ET

Zymeworks to Present at Bloom Burton & Co. Healthcare Investor Conference 2018

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will present at the upcoming Bloom Burton & Co. Healthcare Investor Conference taking place May 2-3, 2018 in Toronto, Canada.

Apr 25, 2018 06:00 am ET

Zymeworks Announces Selection of ZW25 Abstract for Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, announced today that the abstract highlighting new data from the Company’s adaptive Phase 1 clinical trial for ZW25 has been selected for an oral presentation at the American Society of Clinical Oncology (ASCO) being held in Chicago from June 1 through 5, 2018.

Apr 23, 2018 04:05 pm ET

Zymeworks and Celgene Expand Bispecific Antibody Collaboration

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that Celgene Corporation has exercised its right to expand its collaboration agreement for the research, development, and commercialization of bispecific antibody therapeutics using Zymeworks’ Azymetric™ platform.

Apr 17, 2018 05:00 am ET

Zymeworks Presents Preclinical Data at the Annual Meeting of the American Association for Cancer Research

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today presented preclinical data on ZW49, its lead bispecific antibody-drug conjugate candidate (ADC) and its ZymeLink ADC platform. As previously reported, Zymeworks expects to file an Investigational New Drug (IND) application this year in order to begin clinical trials with ZW49 for patients with HER2-expressing cancers.

Mar 14, 2018 04:05 pm ET

Zymeworks Advances Clinical Candidate Incorporating Technology from Kairos Acquisition

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that ZW49 is the first product candidate selected for clinical development utilizing the ZymeLink™ antibody-drug conjugate (ADC) platform, acquired as part of the Company’s 2016 acquisition of Kairos Therapeutics. ZW49 was developed by leveraging ZymeLink in combination with Zymeworks’ flagship Azymetric™ bispecific platform. The Company expects to file an Investigational New Drug (IND) application this year in ord

Mar 14, 2018 04:05 pm ET

Zymeworks Reports 2017 Year-End Financial Results

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported financial results for the year ended December 31, 2017.

Mar 07, 2018 04:05 pm ET

Zymeworks to Present at Barclays 2018 Global Healthcare Conference

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will present at the upcoming Barclays Global Healthcare Conference taking place March 13-15, 2018 in Miami Beach, Florida.

Feb 28, 2018 04:05 pm ET

Zymeworks Opening Clinical Sites in Canada

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the addition of new clinical sites in Canada and the United States for its ongoing adaptive Phase 1 study of the company’s lead clinical candidate, ZW25. ZW25 is a novel bispecific antibody developed using Zymeworks’ proprietary Azymetric™ platform and targets two distinct domains of the HER2 receptor resulting in multiple differentiated mechanisms of action.

Jan 07, 2018 07:00 pm ET

Zymeworks Highlights Key 2017 Accomplishments and Announces 2018 Priorities

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today provided key accomplishments from the past year and announced priorities for 2018.

Dec 05, 2017 05:00 am ET

Zymeworks Presents Results of the Completed Dose Escalation Portion of the Ongoing Phase 1 Study of ZW25 at the San Antonio Breast Cancer Symposium

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics, today presented the completed dose escalation portion of its Phase 1 study of ZW25, a novel Azymetric™ bispecific antibody targeting two distinct domains of the HER2 receptor. The HER2–mediated signaling pathway is believed to contribute to tumor growth in a number of cancers.

Nov 13, 2017 04:15 pm ET

Zymeworks to Present at Upcoming 2017 Stifel Healthcare Conference

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, today announced it will present at the upcoming 2017 Stifel Healthcare Conference taking place November 14-15, 2017 in New York City, New York. The presentation will be November 15, 2017 at 3:30 p.m. ET.

Nov 13, 2017 05:00 am ET

Zymeworks Announces License Agreement with Johnson & Johnson Innovation to Develop and Commercialize Next Generation Bispecific Antibody Therapeutics

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, today announced it has executed a licensing agreement with Janssen Biotech, Inc. (“Janssen”), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The deal was facilitated by Johnson & Johnson Innovation.

Nov 08, 2017 04:15 pm ET

Zymeworks Reports Third Quarter 2017 Financial Results and Provides Business Update

Jun 04, 2017 10:06 pm ET

Zymeworks Inc. Closes the Market

TORONTO, June 2, 2017 /CNW/ - Dr. Ali Tehrani, President & Chief Executive Officer, Zymeworks Inc. (ZYME), joined Ungad Chadda, President, Capital Formation, Equity Capital Markets, TMX Group to close the market. Zymeworks is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer. Zymeworks Inc. commenced trading on Toronto Stock Exchange on May 3, 2017.

Apr 28, 2017 10:59 am ET

IIROC Trade Resumption - ZYME

TORONTO, April 28, 2017 /CNW/ - Trading resumes in:

Apr 28, 2017 08:55 am ET

IIROC Trading Halt - ZYME

TORONTO, April 28, 2017 /CNW/ - The following issues have been halted by IIROC:

Ad blocking detected

Zymeworks Inc. (T:ZYME)

Business Focus: N/A